Evaluation of community‐based treatment for drug‐resistant tuberculosis in Bangladesh

• DOI: 10.1111/tmi.12625
• Publication Date: 2015-10-22T09:59:06Z
• Authors: Joseph S. Cavanaugh; Ekaterina Kurbatova; Negar N. Alami; Joan Mangan; Zinia Sultana; Shahriar Ahmed; Vikarunessa Begum; Sabera Sultana; Paul Daru; Julia Ershova; Alexander Golubkov; Sayera Banu; James D. Heffelfi...
• Keywords: 0303 health sciences; 03 medical and health sciences

AbstractObjectiveDrug‐resistant tuberculosis (TB) threatens global TB control because it is difficult to diagnose and treat. Community‐based programmatic management of drug‐resistant TB (cPMDT) has made therapy easier for patients, but data on these models are scarce. Bangladesh initiated cPMDT in 2012, and in 2013, we sought to evaluate programme performance.MethodsIn this retrospective review, we abstracted demographic, clinical, microbiologic and treatment outcome data for all patients enrolled in the cPMDT programme over 6 months in three districts of Bangladesh. We interviewed a convenience sample of patients about their experience in the programme.ResultsChart review was performed on 77 patients. Sputum smears and cultures were performed, on average, once every 1.35 and 1.36 months, respectively. Among 74 initially culture‐positive patients, 70 (95%) converted their cultures and 69 (93%) patients converted the cultures before the sixth month. Fifty‐two (68%) patients had evidence of screening for adverse events. We found written documentation of musculoskeletal complaints for 16 (21%) patients, gastrointestinal adverse events for 16 (21%), hearing loss for eight (10%) and psychiatric events for four (5%) patients; conversely, on interview of 60 patients, 55 (92%) reported musculoskeletal complaints, 54 (90%) reported nausea, 36 (60%) reported hearing loss, and 36 (60%) reported psychiatric disorders.ConclusionsThe cPMDT programme in Bangladesh appears to be programmatically feasible and clinically effective; however, inadequate monitoring of adverse events raises some concern. As the programme is brought to scale nationwide, renewed efforts at monitoring adverse events should be prioritised.